<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00392548</url>
  </required_header>
  <id_info>
    <org_study_id>RTOG0611</org_study_id>
    <nct_id>NCT00392548</nct_id>
  </id_info>
  <brief_title>URINARY VEGF Levels in GBM Patients on Radiation Treatment Protocol</brief_title>
  <official_title>Urinary VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <brief_summary>
    <textblock>
      Study of the urinary vascular endothelial growth factor (VEGF) levels in patients with
      glioblastoma, receiving standard therapy.

      Hypothesis: that urinary VEGF levels can serve as a predictor of treatment response and
      survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Measurement of urinary VEGF levels pre treatment,immediately after treatment, and 1 month
      after treatment
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2006</start_date>
  <completion_date>October 2006</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population, Natural History</observational_model>
    <time_perspective>Longitudinal, Prospective</time_perspective>
  </study_design_info>
  <enrollment>130</enrollment>
  <condition>Glioblastoma</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must be enrolled on an RTOG GBM study that prescribes 6000 cGy of radiation
             therapy.

          -  Patient must meet the eligibility requirements for the RTOG treatment study. (If the
             patient is deemed retrospectively ineligible for the RTOG treatment study, the patient
             will likewise be ineligible for this study.)

          -  Patient must sign a study-specific informed consent for RTOG 0611 prior to study
             entry.

        Exclusion Criteria:

          -  Patient not able to receive 6000 cGy of radiation therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah T Blumenthal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel-Aviv Sourasky Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deborah T Blumenthal, MD</last_name>
    <phone>011972524266304</phone>
    <email>deborahblumenthal@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lina Vizelman, BS</last_name>
    <phone>01197236977532</phone>
    <email>linav@tasmc.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Deborah T Blumenthal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felix Bokstein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2006</study_first_submitted>
  <study_first_submitted_qc>October 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2006</study_first_posted>
  <last_update_submitted>October 25, 2006</last_update_submitted>
  <last_update_submitted_qc>October 25, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2006</last_update_posted>
  <keyword>GBM</keyword>
  <keyword>glioblastoma</keyword>
  <keyword>urine</keyword>
  <keyword>VEGF</keyword>
  <keyword>radiation</keyword>
  <keyword>Patients must be enrolled to an RTOG GBM study that prescribes 6000 cGy of radiation therapy.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

